Dexrazoxane provided moderate protection in a catecholamine model of severe cardiotoxicity

Canadian Journal of Physiology and Pharmacology

Volumn 90, Issue 4, 2012, Pages 473-484

  Zatloukalová, Libuše ^a   Filipský, Tomáš ^a   Mladěnka, Přemysl ^a   Semecký, Vladimír ^a   Macáková, Kateřina ^a   Holečková, Magdalena ^b   Vávrová, Jaroslava ^b   Palicka, Vladimir ^b   Hrdina, Radomír ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Acute myocardial infarction; Cardiotoxicity; Catecholamine; Dexrazoxane; Iron; Isoprenaline; Myocardium

Indexed keywords

CATECHOLAMINE; ISOPRENALINE; RAZOXANE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIOVENTRICULAR BLOCK; CARDIOTOXICITY; CONTROLLED STUDY; FENTON REACTION; HEART FAILURE; HEART HEMODYNAMICS; HEART PROTECTION; HEART VENTRICLE FIBRILLATION; HEMODYNAMIC PARAMETERS; HISTOLOGY; IN VITRO STUDY; IRON CHELATION; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CALCIUM; CARDIOTONIC AGENTS; DISEASE MODELS, ANIMAL; HEMODYNAMICS; IRON; IRON CHELATING AGENTS; ISOPROTERENOL; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; RATS; RATS, WISTAR; RAZOXANE;

EID: 84859142159     PISSN: 00084212     EISSN: 12057541     Source Type: Journal    
DOI: 10.1139/Y2012-009     Document Type: Article

References (51)

1. Barta, J., Sanganalmath, S.K., Kumamoto, H., Takeda, N., Edes, I., and Dhalla, N.S. 2008. Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality. Cardiovasc. Toxicol. 8(3): 127-135. doi:10.1007/s12012-008-9019-x. PMID:18751928.
2. Beinfield, W.H., and Lehr, D. 1968. QRS-T variations in the rat electrocardiogram. Am. J. Physiol. 214(1): 197-204. PMID: 5634526.
3. Berenshtein, E., Vaisman, B., Goldberg-Langerman, C., Kitrossky, N., Konijn, A.M., and Chevion, M. 2002. Roles of ferritin and iron in ischemic preconditioning of the heart. Mol. Cell. Biochem. 234-235(1-2): 283-292. doi:10.1023/A:1015923202082. PMID:12162445.
4. Bernier, M., Hearse, D.J., and Manning, A.S. 1986. Reperfusioninduced arrhythmias and oxygen-derived free radicals. Studies with "anti-free radical" interventions and a free radical-generating system in the isolated perfused rat heart. Circ. Res. 58(3): 331-340. PMID:3087653.
5. Blasig, I.E., Zipper, J., Muschick, P., Modersohn, D., and Lowe, H. 1985. Absolute and relative myocardial ischemia by isoproterenol overdosage. Biomed. Biochim. Acta, 44(11-12): 1641-1649.PMID:4091837.
6. Bloom, S., and Davis, D.L. 1972. Calcium as mediator of isoproterenol-induced myocardial necrosis. Am. J. Pathol. 69(3): 459-470. PMID:5086900.
7. Buss, J.L., and Hasinoff, B.B. 1995. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187). Arch. Biochem. Biophys. 317(1): 121-127. doi:10.1006/abbi.1995.1143. PMID:7872773.
8. Carll, A.P., Willis, M.S., Lust, R.M., Costa, D.L., and Farraj, A.K. 2011. Merits of non-invasive rat models of left ventricular heart failure. Cardiovasc. Toxicol. 11(2): 91-112. doi:10.1007/s12012-011-9103-5. PMID:21279739.
9. Chagoya de Sánchez, V., Hernández-Muñoz, R., López-Barrera, F., Yañez, L., Vidrio, S., Suárez, J., et al. 1997. Sequential changes of energy metabolism and mitochondrial function in myocardial infarction induced by isoproterenol in rats: a long-term and integrative study. Can. J. Physiol. Pharmacol. 75(12): 1300-1311.doi:10.1139/y97-154. PMID:9580216.
10. Clements-Jewery, H., Hearse, D.J., and Curtis, M.J. 2002. Independent contribution of catecholamines to arrhythmogenesis during evolving infarction in the isolated rat heart. Br. J. Pharmacol. 135(3): 807-815. doi:10.1038/sj.bjp.0704509. PMID:11834629.
11. Cohen, A.R., Galanello, R., Pennell, D.J., Cunningham, M.J., and Vichinsky, E. 2004. Thalassemia. Hematology Am. Soc. Hematol. Educ. Program, 2004: 14-34. doi:10.1182/asheducation-2004.1.14.
12. Cvetković, R.S., and Scott, L.J. 2005. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs, 65(7): 1005-1024. PMID:15892593.
13. Dawson, K.M. 1975. Studies on the stability and cellular distribution of dioxopiperazines in cultured BHK-21S cells. Biochem. Pharmacol. 24(24): 2249-2253. doi:10.1016/0006-2952(75)90262-2. PMID:1240759.
14. Diop, N.K., Vitellaro, L.K., Arnold, P., Shang, M., and Marusak, R. A. 2000. Iron complexes of the cardioprotective agent dexrazoxane (ICRF-187) and its desmethyl derivative, ICRF-154: solid state structure, solution thermodynamics, and DNA cleavage activity. J. Inorg. Biochem. 78(3): 209-216. doi:10.1016/S0162-0134(00)00013-1. PMID:10805177.
15. Filipský, T., Mladěnka, P., Macáková, K., Hrdina, R., Saso, L., Marchetti, F., and Pettinari, C. 2011. In vitro characteristics of 1- phenyl-3-methyl-4-acylpyrazol-5-ones iron chelators. Biochimie, 94(1): 125-131. PMID:21986369.
16. Flandina, C., Sanguedolce, R., Rausa, L., and D'Alessandro, N. 1990. Ameliorative effects of ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl- 1-yl)propane] on the cardiotoxicity induced by doxorubicin or by isoproterenol in the mouse. Res. Commun. Chem. Pathol. Pharmacol. 70(3): 259-272. PMID:2128759.
17. Galetta, F., Franzoni, F., Cervetti, G., Cecconi, N., Carpi, A., Petrini, M., and Santoro, G. 2005. Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed. Pharmacother. 59(10): 541-544. doi:10.1016/j.biopha.2004.12.003. PMID:16325366.
18. Galetta, F., Franzoni, F., Cervetti, G., Regoli, F., Fallahi, P., Tocchini, L., et al. 2009. In vitro and in vivo study on the antioxidant activity of dexrazoxane. Biomed. Pharmacother. 64(4): 259-263. PMID:19932589.
19. Hasinoff, B.B. 1998. Chemistry of dexrazoxane and analogues. Semin. Oncol. 25(4 Suppl 10): 3-9.PMID:9768817.
20. Hasinoff, B.B. 2002. Dexrazoxane (ICRF-187) protects cardiac my ocytes against hypoxia-reoxygenation damage. Cardiovasc. Toxicol. 2(2): 111-118. doi:10.1385/CT:2:2:111. PMID:12271154.
21. Hasinoff, B.B., and Aoyama, R.G. 1999a. Relative plasma levels of th e cardioprotective drug dexrazoxane and its two active ringopened metabolites in the rat. Drug Metab. Dispos. 27(2): 265-268. PMID:9929514.
22. Hasinoff, B.B., and Aoyama, R.G. 1999b. Stereoselective metabolism of dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). Chirality,11(4): 286-290. doi:10.1002/(SICI)1520-636X(1999)11:4<286::AID-CHIR5>3.0.CO;2-5. PMID:10224655.
23. Hašková, P., Koubková, L., Vávrová, A., Macková, E., Hrušková, K., Kovaříková, P., et al. 2011a. Comparison of various iron chelators used in clinical practice as protecting agents against catecholamineinduced oxidative injury and cardiotoxicity. Toxicology, 289(2-3): 122-131. doi:10.1016/j.tox.2011.08.006. PMID:21864640.
24. Hašková, P., Kovaříkova, P., Koubková, L., Vávrová, A., Macková, E., and Šimůnek, T. 2011b. Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity. Free Radic. Biol. Med. 50(4): 537-549.doi:10.1016/j.freeradbiomed.2010.12.004. PMID:21147217.
25. Hrdina, R., Gersl, V., Klimtova, I., Simůnek, T., Machackova, J., and Adamcova, M. 2000. Anthracycline-induced cardiotoxicity. Acta Medica (Hradec Kralove), 43(3): 75-82. PMID:11089274.
26. Huang, Z.X., May, P.M., Quinlan, K.M., Williams, D.R., and Creighton, A.M. 1982. Metal binding by pharmaceuticals. Part 2. Interactions of Ca(II), Cu(II), Fe(II), Mg(II), Mn(II) and Zn(II) with the intracellular hydrolysis products of the antitumour agent ICRF 159 and its inactive homologue ICRF 192. Agents Actions, 12(4): 536-542. doi:10.1007/BF01965940. PMID:7180739.
27. Hüsken, B.C., de Jong, J., Beekman, B., Onderwater, R.C., van der Vijgh, W.J., and Bast, A. 1995. Modulation of the in vitro cardiotoxicity of doxorubicin by flavonoids. Cancer Chemother. Pharmacol. 37(1-2): 55-62. doi:10.1007/BF00685629. PMID:7497597.
28. Jordan, J.E., Zhao, Z.Q., and Vinten-Johansen, J. 1999. The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc. Res. 43(4): 860-878. doi:10.1016/S0008-6363(99)00187-X.PMID:10615413.
29. Kalinowski, D.S., and Richardson, D.R. 2005. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57(4): 547-583. doi:10.1124/pr.57.4.2. PMID:16382108.
30. Kloner, R.A. 2006. Natural and unnatural triggers of myocardial infarction. Prog. Cardiovasc. Dis. 48(4): 285-300. doi:10.1016/j.pcad.2005.07.001. PMID:16517249.
31. Lameris, T.W., de Zeeuw, S., Alberts, G., Boomsma, F., Duncker, D. J., Verdouw, P.D., et al. 2000. Time course and mechanism of myocardial catecholamine release during transient ischemia in vivo. Circulation, 101(22): 2645-2650. PMID:10840018.
32. Liu, Z.D., and Hider, R.C. 2002. Design of clinically useful iron(III)- selective chelators. Med. Res. Rev. 22(1): 26-64. doi:10.1002/med.1027. PMID:11746175.
33. Mladenka, P., Hrdina, R., Hübl, M., and Simůnek, T. 2005. The fate of iron in the organism and its regulatory pathways. Acta Medica (Hradec Kralove), 48(3-4): 127-135. PMID:16640025.
34. Mladenka, P., Hrdina, R., Bobrovova, Z., Semecky, V., Vavrova, J., Holeckova, M., et al. 2009a. Cardiac biomarkers in a model of acute catecholamine cardiotoxicity. Hum. Exp. Toxicol. 28(10): 631-640. doi:10.1177/0960327109350665. PMID:19812120.
35. Mladenka, P., Kalinowski, D.S., Haskova, P., Bobrovova, Z., Hrdina, R., Simůnek, T., et al. 2009b. The novel iron chelator, 2- pyridylcarboxaldehyde 2-thiophenecarboxyl hydrazone, reduces catecholamine-mediated myocardial toxicity. Chem. Res. Toxicol. 22(1): 208-217. doi:10.1021/tx800331j. PMID:19172757.
36. Mladenka, P., Semecky, V., Bobrovova, Z., Nachtigal, P., Vavrova, J., Holeckova, M., et al. 2009c. The effects of lactoferrin in a rat model of catecholamine cardiotoxicity. Biometals, 22(2): 353-361.doi:10.1007/s10534-008-9172-5. PMID:18982411.
37. Mladenka, P., Zatloukalova, L., Simůnek, T., Bobrovova, Z., Semecky, V., Nachtigal, P., et al. 2009d. Direct administration of rutin does not protect against catecholamine cardiotoxicity. Toxicology, 255(1-2): 25-32. doi:10.1016/j.tox.2008.09.027.PMID:18992299.
38. Mladenka, P., Macakova, K., Zatloukalova, L., Rehakova, Z., Singh, B.K., Prasad, A.K., et al. 2010. In vitro interactions of coumarins with iron. Biochimie, 92(9): 1108-1114. doi:10.1016/j.biochi.2010.03.025. PMID:20381579.
39. Neri, M., Cerretani, D., Fiaschi, A.I., Laghi, P.F., Lazzerini, P.E., Maffione, A.B., et al. 2007. Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats. J. Cell. Mol. Med. 11(1): 156-170. doi:10.1111/j.1582-4934.2007.00009.x. PMID:17367510.
40. Persoon-Rothert, M., van der Valk-Kokshoorn, E.J., Egas-Kenniphaas, J.M., Mauve, I., and van der Laarse, A. 1989. Iso proterenolinduced cytotoxicity in neonatal rat heart cell cultures is mediated by free radical formation. J. Mol. Cell. Cardiol. 21(12): 1285-1291. doi:10.1016/0022-2828(89)90674-3. PMID:2632811.
41. Popelová, O., Sterba, M., Simůnek, T., Mazurová, Y., Guncová, I., Hroch, M., et al. 2008. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo. J. Pharmacol. Exp. Ther. 326(1): 259-269. doi:10.1124/jpet.108.137604. PMID:18434588.
42. Popelová, O., Sterba, M., Hasková, P., Simůnek, T., Hroch, M., Guncová, I., et al. 2009. Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death. Br. J. Cancer, 101(5):792-802. doi:10.1038/sj.bjc.6605192. PMID:19623174.
43. Ramu, E., Korach, A., Houminer, E., Schneider, A., Elami, A., and Schwalb, H. 2006. Dexrazoxane prevents myocardial ischemia/ reperfusion-induced oxidative stress in the rat heart. Cardiovasc. Drugs Ther. 20(5): 343-348. doi:10.1007/s10557-006-0497-4.PMID:17119874.
44. Remião, F., Carvalho, M., Carmo, H., Carvalho, F., and Bastos, M.L. 2002. Cu2+-induced isoproterenol oxidation into isoprenochrome in adult rat calcium-tolerant cardiomyocytes. Chem. Res. Toxicol. 15(6): 861-869. doi:10.1021/tx025518q. PMID:12067254.
45. Rona, G. 1985. Catecholamine cardiotoxicity. J. Mol. Cell. Cardiol. 17(4): 291-306. doi:10.1016/S0022-2828(85)80130-9. PMID:3894676.
46. Simůnek, T., Stérba, M., Popelová, O., Adamcová, M., Hrdina, R., and Gersl, V. 2009. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 61(1): 154-171. PMID:19307704.
47. Singal, P.K., Kapur, N., Dhillon, K.S., Beamish, R.E., and Dhalla, N. S. 1982. Role of free radicals in catecholamine-induced cardiomyopathy. Can. J. Physiol. Pharmacol. 60(11): 1390-1397. doi:10.1139/y82-207. PMID:7151008.
48. Spiller, P., and Webb-Peploe, M.M. 1985. Blood flow. Eur. Heart J. 6 (Suppl. C): 11-18. PMID:4076218.
49. Tetef, M.L., Synold, T.W., Chow, W., Leong, L., Margolin, K., Morgan, R., et al. 2001. Phase I trial of 96-hour continuous infusion of dexrazoxane in patients with advanced malignancies. Clin. Cancer Res. 7(6): 1569-1576. PMID:11410492.
50. Thomas, C., Vile, G.F., and Winterbourn, C.C. 1993. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction. Biochem. Pharmacol. 45(10): 1967-1972. doi:10.1016/0006-2952(93)90005-H. PMID:8390256.
51. Von Hoff, D.D., Howser, D., Lewis, B.J., Holcenberg, J., Weiss, R.B., and Young, R.C. 1981. Phase I study of ICRF-187 using a daily for 3 days schedule. Cancer Treat. Rep. 65(3-4): 249-252. PMID:6786738.